Loading…
Loading…
RCAR does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RCAR and 80,000+ other tickers.
See exactly how RCAR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RCAR and 80,000+ other tickers.
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly…
RenovaCare (OTCMKTS:RCAR - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability. Insider and Institutional Ownership 10.1% of Biofrontera shares are owned
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--RenovaCare Inc. (OTC: RCAR): IN THE EIGHTH JUDICIAL DISTRICT COURT OF THE STATE OF NEVADA IN AND FOR CLARK COUNTY PETER RIGSBY, Derivatively on Behalf of RENOVACARE, INC., Plaintiff, v. HARMEL S. RAYAT, KAIYO NEDD, ALAN L. RUBINO, THOMAS BOLD, ROBERT W. COOK, STEPHEN YAN-KLASSEN, and KENNETH KIRKLAND, Defendants, -and- RENOVACARE, INC., a Nevada Corporation, Nominal Defendant. ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) Case No. A-22-850369-C Dept.
NEWARK, N.J., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP announces that the United States District Court for the District of New Jersey has approved the following announcement of a proposed class action settlement that would benefit purchasers of RenovaCare, Inc. securities (OTC: RCAR):
SCOTTSDALE, Ariz., May 03, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced the termination of its July 1, 2020 Strategic Research and Development Agreement with StemCell Systems GmbH (SCS) and the closure of the RenovaCare R&D Innovation Center in Berlin, Germany. This decision ceases on-going development of the prototype for the closed, automated Cell Isolation Device and the portable, disposable SkinGun™ spray device. Development may resume at SCS or other Contract Manufacturing Organizations, upon the availability of adequate funds.
Wilmington, Delaware--(Newsfile Corp. - April 14, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of RenovaCare, Inc. (OTC Pink: RCAR) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-renovacare-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on...